Jemma Buchalter et al. are also evaluating whether anti-CTLA4 doses on day 1 lead to a stronger immune response, so far they have found that Tremelimumab (Day 1 only) and Durvalumab in combination with TACE is safe and feasible in patients with HCC [144]. Here, CTLA4 is linked to hepatocellular carcinoma.